Can a powerful drug cocktail halt multiple myeloma before it starts?
NCT ID NCT04933539
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 9 times
Summary
This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active multiple myeloma and causing organ damage. Fourteen participants will receive the drugs in cycles, followed by daratumumab alone, and will be monitored for life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab, carfilzomib, and dexamethasone
- What this could lead to
- If successful, this could offer a way to delay or prevent smoldering multiple myeloma from turning into active disease, potentially reducing organ damage.
- What could go wrong
- This is a small, early-phase trial with only 14 participants, so results may not apply broadly. The drug combination can cause side effects like heart or lung issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact